Impact of Circadian Rhythm on Immunotherapy

This study is investigating whether the time of day that cancer immunotherapy (checkpoint inhibitor drugs) is administered affects how well it works. Researchers believe the body's internal clock (circadian rhythm) may influence immune function and therefore the effectiveness of these drugs for lung cancer and other solid tumors. **You may be eligible if...** - You have advanced or metastatic non-small cell lung cancer (NSCLC) or another solid tumor for which a PD-1/PD-L1 immunotherapy is an approved first-line treatment - You have not yet received checkpoint immunotherapy (or are receiving it in an induction phase and transitioning to maintenance) - You are willing to be randomized to receive your infusion in the morning OR later in the day/evening - Your cancer treatment plan is to receive PD-1/PD-L1 immunotherapy alone or in combination with approved drugs **You may NOT be eligible if...** - You have already received checkpoint immunotherapy in a prior line of treatment - You have a scheduling conflict or medical issue that prevents you from receiving infusions at an assigned time of day - You are not eligible for PD-1/PD-L1 immunotherapy per your oncologist Talk to your doctor to see if this trial is right for you.